P2P, or not P2P, that is the question
As the 16 January, 2015 deadline for responding to the controversial P2P draft report draws near, and in the interests of balance and representing the whole community, Phoenix Rising presents two differing views on how to react. Today, Clark Ellis flags up important content to...
Discuss the article on the Forums.

Antiviral drug resistance in herpesviruses other than cytomegalovirus.

Discussion in 'Other Health News and Research' started by Ecoclimber, Mar 10, 2014.

  1. Ecoclimber

    Ecoclimber No Longer On PR

    Messages:
    788
    Likes:
    1,619
    Rev Med Virol. 2014 Mar 7. doi: 10.1002/rmv.1787. [Epub ahead of print]
    Antiviral drug resistance in herpesviruses other than cytomegalovirus.
    Piret J1, Boivin G.
    Author information

    Abstract

    The discovery of acyclovir (ACV), a nucleoside analogue, more than 30 years ago, represents a milestone in the management of HSV and VZV infections. The modest activity of ACV against CMV prompted the development of another nucleoside analogue, ganciclovir, for the management of systemic and organ-specific CMV diseases.

    Second-line agents such as the pyrophosphate analogue foscarnet and the nucleotide analogue cidofovir have been approved subsequently. In contrast to ACV and ganciclovir, the latter drugs do not require selective phosphorylation by viral protein kinases to be converted into their active forms.

    Since the introduction of these antivirals, the emergence of drug-resistant mutants has been constantly reported particularly in severely immunocompromised patients such as bone marrow and solid organ transplant recipients as well as HIV-infected individuals. In this manuscript, we discuss the characteristics of the antiviral agents currently approved for the management of HSV, VZV and CMV diseases. In recent years, the resistance of CMV to antiviral drugs has been extensively reviewed.

    The emergence of antiviral drug resistance is also observed with other members of the Herpesviridae family, namely HSV-1, HSV-2, VZV and HHV-6, which are the focus of this review. More specifically, we describe the laboratory methods for assessing drug susceptibilities, the frequency and clinical significance of drug-resistant infections and their management. Copyright © 2014 John Wiley & Sons, Ltd.

    Copyright © 2014 John Wiley & Sons, Ltd.
     
    Iquitos likes this.

See more popular forum discussions.

Share This Page